Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.105 −32.3% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.395 −1.2% LIB 0.780 −14.3% SMY 0.290 +23.4% S 0.105 −32.3% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.395 −1.2% LIB 0.780 −14.3% SMY 0.290 +23.4%
Other

Canopy Growth adds new Spectrum softgels in Australia

By The Northwire Desk — AI Analysis Nov 18, 2025 · 11:48 WEED · 1.47 Canopy Growth Corp
WEED · Price

Executive Summary

  • Canopy Growth Corp. has expanded its Spectrum Therapeutics portfolio in Australia with the introduction of new softgel capsule formats, enhancing its medical cannabis offerings in the region.
  • The new products include three specific softgel formulations: Spectrum Yellow (CBD 20mg), Spectrum Red (THC 10mg), and Spectrum Blue (Balanced THC 2.5mg: CBD 3.75mg).
  • These softgels complement existing oils and flower products from Spectrum Therapeutics, Tweed, 7Acres, and TWD, which are already available to Australian patients through authorized prescribers.

Key Details

  • New Product Formats:
    • Spectrum Yellow Cannabis Oil Softgels: Contains 20 milligrams of CBD.
    • Spectrum Red Cannabis Oil Softgels: Contains 10 mg of THC.
    • Spectrum Blue Cannabis Oil Softgels: Contains a balanced ratio of 2.5 mg THC and 3.75 mg CBD.
  • Market Availability: The softgels are available to patients in Australia through authorized prescribers.
  • Strategic Context: The expansion is described as a key driver of the company's global medical strategy, aiming to meet patient demand for variety, quality, and convenience in product formats.
  • Complementary Products: The new softgels join existing Spectrum Therapeutics oils and flower, as well as flower products from brands Tweed, 7Acres, and TWD.

Notable Quotes

  • "Expanding our portfolio in established markets like Australia is a key driver of our global medical strategy. Softgels deepen our offering and reinforce our commitment to meeting the needs of patients in this important international market." — Luc Mongeau, Chief Executive Officer
  • "Patients continue to ask for a variety of formats that deliver both quality and convenience. Adding softgels to the Spectrum Therapeutics portfolio gives prescribers and patients more choice while supporting the continued growth of our international business." — Andrew Bevan, Senior Vice-President, Global Medical
Read the original news release →

More from Canopy Growth Corp

Jun 15, 2026 · 07:00

Balance sheet repair and MTL integration buy time, but margin compression and cash burn keep profitability distant.

Earnings Jun 08, 2026 · 07:30

Product line extension and award recognition fail to offset structural margin pressures and market skepticism.

Other May 29, 2026 · 07:00

Accounting Restatement and Management Cease Trade Order Loom Over Germany Expansion

Regulatory May 15, 2026 · 17:00

Canopy Growth’s accounting stumble is a self-inflicted wound that muddies the recovery narrative just as operational momentum was building.

Other May 14, 2026 · 08:45

Canopy Growth’s latest product tweak gets swept into a wider European boom story, but the stock’s rebound remains more about survival than fireworks.

M&A / Property May 07, 2026 · 07:30

Canopy Growth Expands Medical Portfolio as Integration Risks Linger Despite Liquidity Boost

Production / Operations